The estimated Net Worth of Erich Sager is at least $1.57 Milion dollars as of 24 February 2006. Erich Sager owns over 11,500 units of Biomarin Pharmaceutical stock worth over $1,255,507 and over the last 21 years Erich sold BMRN stock worth over $314,700.
Erich has made over 6 trades of the Biomarin Pharmaceutical stock since 2004, according to the Form 4 filled with the SEC. Most recently Erich exercised 11,500 units of BMRN stock worth $80,500 on 24 February 2006.
The largest trade Erich's ever made was selling 22,500 units of Biomarin Pharmaceutical stock on 30 November 2005 worth over $234,450. On average, Erich trades about 8,125 units every 98 days since 2003. As of 24 February 2006 Erich still owns at least 14,809 units of Biomarin Pharmaceutical stock.
You can see the complete history of Erich Sager stock trades at the bottom of the page.
Erich's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 371 BEL MARIN KEYS BLVD., #210, NOVATO, CA, 94949.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy a Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: